INTROGEN THERAPEUTICS INC Form 8-K August 12, 2004

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2004

Introgen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-21291	74-2704230
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1 Congress Avenue, S	Suite 1850, Austin, Texas	78701
(Address of principal executive offices)		(Zip Code)
	one number, including area	1 (510) 700 0210

TABLE OF CONTENTS

Item 7. Financial Statements and Exhibits.

Item 12. Results of Operations and Financial Condition.

SIGNATURES

INDEX TO EXHIBITS

Press Release

Table of Contents

Item 7. Financial Statements and Exhibits.

- (c) Exhibits.
- 99.1 Press Release dated August 12, 2004.

Item 12. Results of Operations and Financial Condition.

On August 12, 2004, Introgen Therapeutics, Inc. issued its press release announcing financial results for the three months ended June 30, 2004. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 12, 2004 INTROGEN THERAPEUTICS, INC.

/s/ JAMES W. ALBRECHT, JR.

James W. Albrecht, Jr. Chief Financial Officer

- 2 -

Table of Contents

INDEX TO EXHIBITS

Exhibit Number	Description of Document
99.1	Press Release dated August 12, 2004.